Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for J2Kbio Co., Ltd. (420570:KRX), powered by AI.
J2Kbio Co., Ltd. is currently trading at ₩9,390. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for J2Kbio Co., Ltd. on Alpha Lenz.
J2Kbio Co., Ltd.'s P/E ratio is 20.5.
“J2Kbio Co., Ltd. trades at a P/E of 20.5 (fair value) with solid ROE of 8.2%. 3Y revenue CAGR of 27.2% highlights clear growth momentum.”
Ask for details →J2Kbio Co., Ltd. is a biotechnology company that specializes in the development and manufacturing of biological products. Its primary focus is on leveraging advanced biotechnological processes to create innovative solutions within the healthcare and life sciences industries. The company's product range often includes medical devices, diagnostic tools, and therapeutic biologics, all aimed at improving health outcomes and providing sustainable medical solutions. J2Kbio Co., Ltd. engages in extensive research and development activities, typically collaborating with academic institutions and industry partners to stay at the forefront of biotechnological advancements. Through this approach, it contributes significantly to the progress of personalized medicine and precision healthcare. Positioned within the dynamic and rapidly growing biotech sector, J2Kbio Co., Ltd. plays a crucial role in addressing unmet medical needs and enhancing the quality of life for patients globally. Its emphasis on innovation underscores its importance in the market as a key player driving forward the capabilities and applications of biotechnology.
“J2Kbio Co., Ltd. trades at a P/E of 20.5 (fair value) with solid ROE of 8.2%. 3Y revenue CAGR of 27.2% highlights clear growth momentum.”
Ask for details →J2Kbio Co., Ltd. (ticker: 420570) is a company listed on KRX in the Basic Materials sector (Specialty Chemicals). It has approximately 56 employees. Market cap is $54.9B.
The current price is ₩9,390 with a P/E ratio of 20.54x and P/B of 1.63x.
ROE is 8.21% and operating margin is 8.86%. Annual revenue is $33.0B.